Skip Navigation

European Heart Journal 1993 14(11):1572-1575;
Copyright © 1993 by the European Society of Cardiology.
This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Add to My Personal Archive
Right arrow Download to citation manager
Right arrowRequest Permissions
Google Scholar
Right arrow Articles by ALBAT, B.
Right arrow Articles by THEVENET, A.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by ALBAT, B.
Right arrow Articles by THEVENET, A.
Social Bookmarking
Add to CiteULike   Add to Connotea   Add to Del.icio.us  
What's this?

© 1993 The European Society of Cardiology

Heart transplantation for terminal congestive heart failure in an acromegalic patient

B. ALBAT*,, FF. LECLERCQ{dagger}, I. SERRE{ddagger}, A. FILLE§, P. BALDET{ddagger}, R. GROLLEAU-RAOUX{dagger} and A. THEVENET*

*Service de Transplantation Cardio-Thoracique, Hôpital Arnaud de Villeneuve France
{dagger}Service de Cardiologie, Hôpital Arnaud de Villeneuve France
{ddagger}Service des Maladies Métaboliques et Endocriniennes, Hôpital Lapeyronie France
§Laboratoire d'Anatomie et Cytologie Pathologique B, Hôpital Lapeyronie Montpellier, France

Received 28 October 1992; revised 27 January 1993; .

Correspondence B Albat, Service de Transplantation Cardio-Thoraciques, Hôpital Arnaud de Villeneuve, 34059 Montpellier Cedex, France

Abstract

Dilated hypokinetic cardiomyopathy in an acromegalic patient is an uncommon event. Specific hormonal therapy with octreotide (a somatostatin analogue) is now recognized as able to improve cardiac failure. A case of worsening of cardiac function under such a therapy is described in this report. Octreotide was finally discontinued and a cardiac transplantation performed. Soon after surgery, treatment with octreotide was started again and no other adverse reaction was noticed. Furthermore, no deleterious or synergistic interaction between the somatostatin analogue and cyclosporine A was detected. A pharmacological hypothesis is given to explain the inability of octreotide to counteract cardiac failure. The patient died 6 months after surgery probably because of an acute episode of arrhythmia.

Key Words: Acromegaly • heart failure • heart transplantation • octreotide


Add to CiteULike CiteULike   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us    What's this?




Disclaimer:
Please note that abstracts for content published before 1996 were created through digital scanning and may therefore not exactly replicate the text of the original print issues. All efforts have been made to ensure accuracy, but the Publisher will not be held responsible for any remaining inaccuracies. If you require any further clarification, please contact our Customer Services Department.